BioPharma Dive1 min read
saveWindward prices $175M IPO to advance China-licensed lung drugs
The Swiss biotech has two prospects it sees as having the potential to outcompete AstraZeneca and Amgen's blockbuster asthma treatment Tezspire.
The Swiss biotech has two prospects it sees as having the potential to outcompete AstraZeneca and Amgen's blockbuster asthma treatment Tezspire.
comments(0)
5-min edit window · permanent after that